Project: Multidimensional stratification for treatment of acute kidney injury

Acronym	KIDNEY ATTACK (Reference Number: ERAPERMED2018-142)
Duration	01/03/2019 - 28/02/2022
Project Topic	Annually 2 million people die worldwide from acute kidney injury (AKI). Furthermore, AKI triples the length of hospital stays, the associated costs and readmission rates. AKI represents both a diagnostic and treatment challenge that, although recognized decades ago, are still not solved. Kidney Attack aims to change this status quo by innovative and smart combination of AKI scientific literature, preclinical and clinical omics and patient data to propose early personalized detection of AKI and novel drugs with high translational value. 3 parallel avenues will be pursued to reach this goal: i) We aim to move from the one biomarker-per-disease paradigm to multiomics-based biomarker panels in already available, easily accessible, body fluids for improved description and therefore early detection of AKI. These developed multiomics-based panels will be validated in independent cohorts during the project to show-case their wider clinical application; ii) In parallel to this early detection, we will use these multiomics-based biomarker panels to develop humanized readouts in two major animal AKI models by smart integration of interspecies similarity to improve the translatability of preclinical observations; iii) Specific AKI therapeutics haven been identified but did not made it to the clinic due to the absence of translational value. A large corpus of clinical and preclinical omics data is accessible. In Kidney Attack, we will extract all available AKI omics and associated data from the literature and databases and predict novel/repurposed drugs based on the extracted molecular signatures of AKI. In the next step, a number of these drugs will be screened in the Kidney Attack preclinical models to determine their effect on animal AKI and, upon analysis of their effect on the developed humanized AKI read-out, their translational value. In conclusion, we aim to introduce personalized medicine and novel therapeutics in AKI that is not attainable by classical approaches
Network	ERA PerMed
Call	1st Joint Transnational Call for Proposals (2018)

Project partner

Number	Name	Role	Country
1	Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz	Coordinator	Spain
2	Inserm	Partner	France
3	Mosaiques Diagnostics GmbH	Partner	Germany
4	CEA	Partner	France